Modifying immune response through
- Technology Benefits
- Potentially enhances T cell response in a wider group of cancer patients Improves the understanding of the role of CTLA-4 in auto immune disease and opens up new approaches to treating diseases such as diabetes
- Detailed Technology Description
- CTLA-4 is part of a complicated system that controls T cell activation. When CD28, a molecule expressed on T cells, binds to either CD80 or CD86 expressed on other cells it induces T cell activation. CTLA-4 also binds to CD80 and CD86 and acts to inhibit T cell activation. A soluble version of CTLA-4 could prevent T cell activation by blocking CD80 and CD86 from binding to CD28. In addition, soluble CTLA-4 is released by T cells and occurs naturally in humans. It is elevated in autoimmune diseases however it is not clear how it functions. It would be expected to inhibit T cell activation. Workers at the University have produced a new form of soluble CTLA-4 (sCTLA-4) that exists as a monomeric protein in contrast to CTLA-4 Ig. Surprisingly we have found that soluble CTLA-4 can boost immune responses.
- Supplementary Information
- Inventor: QURESHI, Omar Saleem | SANSOM, David Michael
Priority Number: WO2012127240A3
IPC Current: A61K003800 | G01N003350
Assignee Applicant: The University of Birmingham
Title: IMMUNE ASSAY | ESSAI IMMUNOLOGIQUE
Usefulness: IMMUNE ASSAY | ESSAI IMMUNOLOGIQUE
- Industry
- Biomedical
- Sub Category
- Bioengineering
- *Abstract
-
CTLA-4 is a protein and is one of the most important immune regulators, with potential for use in human cancer therapy. However commercial antibodies that block CTLA-4, and activate the immune system, are effective in only a small percentage of patients, however, in patients where the antibody is effective, massive tumour regression is seen.
- *Principal Investigator
-
Name: Prof. David Sansom
Department:
- Country/Region
- USA
For more information, please click Here
